Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
The Fly
Revolution Medicines appoints Alan Sandler as CDO
13h ago
RVMD
Premium
Ratings
Revolution Medicines: Strategic Positioning and Promising Phase 3 Trials Drive Buy Rating
16h ago
RVMD
Premium
The Fly
Revolution Medicines price target raised to $71 from $70 at JPMorgan
5d ago
RVMD
Premium
The Fly
Revolution Medicines resumed with a Strong Buy at Raymond James
18d ago
RVMD
Premium
The Fly
Revolution Medicines rises 14.2%
19d ago
RVMD
Premium
The Fly
Morning Movers: Kroger rises following second quarter results
19d ago
KR
CNC
Premium
The Fly
Revolution Medicines announces results from daraxonrasib Phase 1 trials
19d ago
RVMD
Premium
Ratings
Promising Position of Revolution Medicines’ Zoldonrasib Justifies Buy Rating
19d ago
RVMD
Premium
The Fly
Revolution Medicines price target raised to $70 from $67 at Wells Fargo
19d ago
RVMD
Premium
Ratings
Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution Medicines
19d ago
RVMD
Premium
Ratings
Promising Clinical Trials and Strategic Design Drive Buy Rating for Revolution Medicines
19d ago
RVMD
Premium
Company Announcements
Revolution Medicines Reports Promising Phase 1 Study Results
19d ago
8K
RVMD
Premium
The Fly
Leerink says competitor data suggest promising view for Revolution’s zoldonrasib
22d ago
RVMD
VSTM
Premium
The Fly
Revolution Medicines initiated with a Buy at Truist
25d ago
RVMD
Premium
The Fly
Piper starts Revolution Medicines at Overweight on daraxonrasib potential
1M ago
RVMD
Premium
The Fly
Revolution Medicines initiated with an Overweight at Piper Sandler
1M ago
RVMD
Premium
The Fly
Revolution Medicines initiated with an Outperform at LifeSci Capital
1M ago
RVMD
Premium
The Fly
Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
2M ago
BJ
PH
Premium
The Fly
Revolution Medicines initiated with an Overweight at Wells Fargo
2M ago
RVMD
Premium
Ratings
Revolution Medicines’ Innovative RAS(ON) Platform and Strategic Collaborations Drive Buy Rating
2M ago
RVMD
Premium
Company Announcements
Revolution Medicines’ Earnings Call: Progress Amid Challenges
2M ago
RVMD
Premium
Ratings
Optimistic Outlook for Revolution Medicines Amid Strategic Developments and Pipeline Progress
2M ago
RVMD
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
